论文部分内容阅读
目的:探讨参麦注射液联合左卡尼汀治疗缺血性心肌病心力衰竭的临床疗效,并观察和分析其对心功能的改善,为临床治疗提供依据。方法:选择医院2014年1月—2015年3月缺血性心肌病心力衰竭患者136例,随机分为对照组和观察组,两组各68例,对照组进行常规治疗,观察组在对照组基础上应用参麦注射液联合左卡尼汀治疗,均连续治疗两周。主要观察治疗效果,症状或体征的改善、应用超声心动图评估治疗前后每搏心输出量(SV)、左室射血分数(LVEF)、左心室收缩末期容积(LVESV)及左心室舒张末期容积(LVEDV)等心功能指标。结果:观察组总有效率为98.53%(67/68),高于对照组92.65%(63/68),差异有统计学意义(P<0.05);观察组乏力、气促、胸闷改善率分别为86.76%(52/68)、88.24%(60/68)和83.82%(57/68),均高于对照组,差异有统计学意义(P<0.05);观察组治疗后SV和LVEF分别为(4.78±0.22)L/min和(76.10±6.93)%,均高于对照组治疗后,差异有统计学意义(P<0.05);观察组治疗后LVESV和LVEDV分别为(74.10±6.93)m L和(85.39±9.62)m L,均第于对照组治疗后,差异有统计学意义(P<0.05)。结论:参麦注射液联合左卡尼汀治疗缺血性心肌病心力衰竭具有较好的临床疗效,能够显著改善患者症状或体征,并提高患者心功能。
Objective: To investigate the clinical efficacy of Shenmai injection combined with levocarnitine in the treatment of heart failure of ischemic cardiomyopathy, and to observe and analyze the improvement of cardiac function, so as to provide the basis for clinical treatment. Methods: One hundred and sixty-six patients with heart failure of ischemic cardiomyopathy from January 2014 to March 2015 in our hospital were randomly divided into control group and observation group, with 68 cases in each group. The control group was treated routinely. In the control group On the basis of Shenmai injection combined with levocarnitine treatment, were treated for two weeks. The main observation of the treatment effect, symptoms or signs of improvement, the application of echocardiography before and after treatment to assess stroke volume (SV), left ventricular ejection fraction (LVEF), left ventricular end systolic volume (LVESV) and left ventricular end-diastolic volume (LVEDV) and other cardiac function indicators. Results: The total effective rate in the observation group was 98.53% (67/68), which was higher than that in the control group (92.65%, 63/68), the difference was statistically significant (P <0.05) (52/68), 88.24% (60/68) and 83.82% (57/68) respectively, which were significantly higher than that of the control group (P <0.05). After treatment, the levels of SV and LVEF (4.78 ± 0.22) L / min and (76.10 ± 6.93)%, respectively, which were significantly higher than those in the control group (P <0.05). The LVESV and LVEDV in the observation group were (74.10 ± 6.93) m L and (85.39 ± 9.62) m L, respectively, were significantly different from those of the control group after treatment (P <0.05). Conclusion: Shenmai injection combined with levocarnitine in the treatment of heart failure of ischemic cardiomyopathy has a good clinical efficacy, can significantly improve the symptoms or signs of patients and improve cardiac function.